Advertisement

Advertisement

CVKD Stock Latest News

Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA

The FlyCadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA

Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial

PremiumCompany Announcements

Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial

5d ago

Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders

PremiumThe Fly

Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders

14d ago

Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright

PremiumThe Fly

Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright

28d ago

Cadrenal Therapeutics Inc trading halted, volatility trading pause

PremiumThe Fly

Cadrenal Therapeutics Inc trading halted, volatility trading pause

1M ago

Cadrenal Therapeutics Inc trading resumes

PremiumThe FlyCadrenal Therapeutics Inc trading resumes

1M ago

Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement

Company Announcements

Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement

1M ago

FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk

Company Announcements

FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk

1M ago

Cadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet

PremiumPre-Earnings

Cadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet

2M ago

Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease

PremiumCompany Announcements

Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease

2M ago

Cadrenal Therapeutics highlights research on 12-LOX inhibition

PremiumThe Fly

Cadrenal Therapeutics highlights research on 12-LOX inhibition

2M ago

Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion

PremiumThe Fly

Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion

2M ago

Cadrenal Highlights Mixed Phase 2 Results for CAD-1005

PremiumCompany AnnouncementsCadrenal Highlights Mixed Phase 2 Results for CAD-1005

2M ago

Cadrenal Therapeutics announces Phase 2 results for CAD-1005

The Fly

Cadrenal Therapeutics announces Phase 2 results for CAD-1005

2M ago

Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution

The Fly

Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution

4M ago

Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity

PremiumCompany Announcements

Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity

4M ago

Cadrenal Therapeutics Announces New Securities Purchase Agreement

PremiumCompany Announcements

Cadrenal Therapeutics Announces New Securities Purchase Agreement

5M ago

Cadrenal Therapeutics Acquires VLX-1005 from Veralox

PremiumCompany Announcements

Cadrenal Therapeutics Acquires VLX-1005 from Veralox

5M ago

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia

PremiumThe Fly

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia

5M ago

Cadrenal Therapeutics Appoints Dr. Golden to Board

PremiumCompany AnnouncementsCadrenal Therapeutics Appoints Dr. Golden to Board

5M ago

Cadrenal Therapeutics appoints Lee Golden to board of directors

The Fly

Cadrenal Therapeutics appoints Lee Golden to board of directors

5M ago

Cadrenal Therapeutics Announces New Stock Offering Program

Company Announcements

Cadrenal Therapeutics Announces New Stock Offering Program

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >